1. Wartenberg D and Thompson WD. Privacy versus public health: the
impact of current confidentiality rules. American Journal of
Public Health . 2010; 100: 407-12.
2. Platt RW, Henry D and Suissa S. The Canadian Network for
Observational Drug Effect Studies (CNODES): Reflections on the first
eight years, and a look to the future. 2019.
3. Platt R, Brown JS, Robb M, et al. The FDA sentinel initiative—an
evolving national resource. The New England journal of medicine .
2018; 379: 2091-3.
4. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for
active surveillance: rationale and design for the Observational Medical
Outcomes Partnership. Annals of internal medicine . 2010; 153:
600-6.
5. Budrionis A and Bellika JG. The learning healthcare system: where are
we now? A systematic review. Journal of biomedical informatics .
2016; 64: 87-92.
6. Maro JC, Platt R, Holmes JH, et al. Design of a national distributed
health data network. Annals of internal medicine . 2009; 151:
341-4.
7. Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian network for
observational drug effect studies. Open Medicine . 2012; 6: e134.
8. Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian Network for
Observational Drug Effect Studies. Open medicine : a
peer-reviewed, independent, open-access journal . 2012; 6: e134-40.
9. Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV and Brown JS.
Launching PCORnet, a national patient-centered clinical research
network. Journal of the American Medical Informatics Association .
2014; 21: 578-82.
10. Agency EM. Data Analysis and Real World Interrogation Network
(DARWIN EU). 2022.
11. Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data
Sciences and Informatics (OHDSI): opportunities for observational
researchers. Studies in health technology and informatics . 2015;
216: 574.
12. Pratt N, Andersen M, Bergman U, et al. Multi‐country rapid adverse
drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN)
antipsychotic and acute hyperglycaemia study. Pharmacoepidemiology
and drug safety . 2013; 22: 915-24.
13. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model
for monitoring immunization safety. Pediatrics . 2011; 127:
S45-S53.
14. Thurin NH, Pajouheshnia R, Roberto G, et al. From Inception to
ConcePTION: Genesis of a Network to Support Better Monitoring and
Communication of Medication Safety During Pregnancy and Breastfeeding.Clinical Pharmacology & Therapeutics . 2022; 111: 321-31.
15. Toh S, Gagne JJ, Rassen JA, Fireman BH, Kulldorff M and Brown JS.
Confounding adjustment in comparative effectiveness research conducted
within distributed research networks. Medical care . 2013; 51:
S4-S10.
16. Toh S, Reichman ME, Houstoun M, et al. Multivariable confounding
adjustment in distributed data networks without sharing of patient‐level
data. Pharmacoepidemiology and drug safety . 2013; 22: 1171-7.
17. Secrest MH, Platt RW, Dormuth CR, et al. Extreme restriction design
as a method for reducing confounding by indication in
pharmacoepidemiologic research. Pharmacoepidemiology and drug
safety . 2020; 29: 26-34.
18. Secrest MH, Platt RW, Reynier P, Dormuth CR, Benedetti A and Filion
KB. Multiple imputation for systematically missing confounders within a
distributed data drug safety network: A simulation study and real-world
example. Pharmacoepidemiology and drug safety . 2020; 29 Suppl 1:
35-44.
19. Rothman KJ, Greenland S and Lash TL. Modern epidemiology .
Wolters Kluwer Health/Lippincott Williams & Wilkins Philadelphia, 2008.
20. Westreich D, Edwards JK, Lesko CR, Cole SR and Stuart EA. Target
Validity and the Hierarchy of Study Designs. Am J Epidemiol .
2019; 188: 438-43.
21. Lesko CR, Ackerman B, Webster-Clark M and Edwards JK. Target
validity: bringing treatment of external validity in line with internal
validity. Current epidemiology reports . 2020; 7: 117-24.
22. Dahabreh IJ, Robertson SE, Steingrimsson JA, Stuart EA and Hernan
MA. Extending inferences from a randomized trial to a new target
population. Statistics in medicine . 2020; 39: 1999-2014.
23. Pearl J and Bareinboim E. External validity: From do-calculus to
transportability across populations. Statistical Science . 2014;
29: 579-95.
24. Webster-Clark M and Breskin A. Directed acyclic graphs, effect
measure modification, and generalizability. American Journal of
Epidemiology . 2021; 190: 322-7.
25. Westreich D, Edwards JK, Lesko CR, Stuart E and Cole SR.
Transportability of Trial Results Using Inverse Odds of Sampling
Weights. Am J Epidemiol . 2017; 186: 1010-4.
26. Dahabreh IJ, Haneuse SJA, Robins JM, et al. Study designs for
extending causal inferences from a randomized trial to a target
population. American journal of epidemiology . 2021; 190: 1632-42.
27. MacPherson H. Pragmatic clinical trials. Complementary
therapies in medicine . 2004; 12: 136-40.
28. Schneeweiss S, Brown JS, Bate A, Trifirò G and Bartels DB. Choosing
among common data models for real‐world data analyses fit for making
decisions about the effectiveness of medical products. Clinical
Pharmacology & Therapeutics . 2020; 107: 827-33.
29. Weissfeld M, Gagne JJ and Izem R. SENTINEL METHODS. 2016.
30. Marin-Martinez F and Sánchez-Meca J. Weighting by inverse variance
or by sample size in random-effects meta-analysis. Educational and
Psychological Measurement . 2010; 70: 56-73.